Cell2B and IPO-Porto Establish Clinical and R&D Collaboration

March 24, 2014 – Lisbon – Cell2B and the Portuguese Institute of Oncology – Porto (IPO-Porto) establish an R&D collaboration for the development of Cell2B’s lead product ImmuneSafe. With this collaboration the clinical center will not only collaborate in the pharmaceutical development studies, including supplying Bone Marrow samples, but also, and more importantly, join the clinical trial network. The Portuguese Institute of Oncology – Porto is the largest hemato-oncology center in Portugal and is ranked top 30 in Europe (out of 600 centers).

Cell2B is a biotech developer of cell therapies for immune and inflammatory diseases. Incorporated in 2011, Cell2B brings together technology developed by its founders at the Massachusetts Institute of Technology (MIT) in Boston and Instituto Superior Técnico (IST) in Lisbon. An early clinical study of the technology showed that it was safe in six patients suffering from Graft-versus-Host-Disease (GvHD). Orphan designation has been granted in Europe for the treatment of GvHD.